Project Grant R01HL174544
Award Date
6/1/25
Completion Date
3/31/29
Dollars Obligated
$523K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $244,589 award supports research to investigate the role of the VPS34 protein in the development and progression of pulmonary arterial hypertension (PAH). Key objectives include examining the regulation and activation of VPS34 in the pulmonary vasculature of PAH patients, determining the...
This federal Project Grant award of $596,809 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to explore the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The project aims to define how MitoNEET regulates pulmonary artery smooth muscle cell (PASMC) mitochondrial function and proliferation in vitro, examine MitoNEET expression and function during PH pathogenesis in vivo...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 2-year, $131,485 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc. to study the role of proline metabolism in pulmonary arterial hypertension (PAH). The research aims to understand how inflammation impairs the regulation of proline in pulmonary artery endothelial cells, potentially leading to increased cell proliferation, collagen synthesis, and vascular remodeling in early-stage...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $498,000.00 to National Jewish Health in Denver, Colorado to conduct research on the role of RNA editing in pulmonary hypertension. The primary objective is to investigate how the enzyme ADAR1, which regulates RNA editing, controls the survival and immune response of pulmonary artery endothelial cells and impacts the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $715,161 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), to conduct research on the epigenetic regulation of pulmonary smooth muscle cell remodeling in pulmonary hypertension. The research aims to elucidate the molecular mechanisms by which the sphingosine kinase 2 (SPHK2) enzyme contributes to vascular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $498,000.00 to the University of Florida to investigate the role of microglia activation and neuroinflammation in the pathophysiology of pulmonary hypertension (PH). The key objectives are to: 1) Evaluate microglia-dependent mechanisms contributing to increased preautonomic neuron activity in the paraventricular nucleus; 2) Determine how TREM2 expression...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research focused on understanding the role of the RNA-binding protein ZFP36 in pulmonary arterial hypertension (PAH). The $1,535,625 award, effective July 20, 2024 through May 31, 2028, will enable researchers at the University of California, Los Angeles (UCLA) to investigate how ZFP36 regulates gene expression and impacts...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $564,445 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to the University of Texas Health Science Center at Houston (UTHealth). The 7-year award, running from March 1, 2025 to December 31, 2031, will support UTHealth's "Hypoxia-Inflammation Program" focused on targeting hypoxia-inducible factors (HIFs) for the treatment of heart and lung diseases. The program encompasses three...
This Project Grant award of $812,189.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to better understand pulmonary hypertension in chronic obstructive pulmonary disease (COPD) patients using advanced CT imaging techniques. The goal is to identify CT imaging features that can predict the presence and subtype of pulmonary hypertension in COPD, which will enable non-invasive screening and diagnosis....
This federal Project Grant award in the amount of $692,768 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to define endothelial cell dysfunction and anoikis resistance in patients with pulmonary arterial hypertension (PAH). The research aims to leverage a "cell biopsy" method to characterize endothelial cell phenotypes and identify key mediators of anoikis resistance...